1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode

 
• By Alaric DeArment

The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.

While SpringWorks is initially pursuing desmoid tumors, multiple myeloma represents a much bigger market • Source: Shutterstock

SpringWorks Therapeutics Inc. hopes to become the first company to win US Food and Drug Administration approval for a drug to treat desmoid tumors, a rare and potentially fatal cancer type, after a successful Phase III study of nirogacestat, and the company is already working on commercialization plans. But the drug may have a bigger opportunity as a combination treatment with cell therapy in multiple myeloma.

SpringWorks announced on 24 May that nirogacestat met the primary endpoint and was generally well tolerated in the Phase III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

GSK’s Blenrep US Setback Could Go From Bad To Worse

 
• By Sushmita Panda

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 
• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.